Gene therapy for cystic fibrosis (CF) has been the subject of intense research over the last twenty-five years or more, using both viral and liposomal delivery methods, but so far without the emergence of a clinical therapy. New approaches to CF gene therapy involving recent improvements to vector systems, both viral and non-viral, as well as new nucleic acid technologies have led to renewed interest in the field. The field of therapeutic gene editing is rapidly developing with the emergence of CRISPR/Cas9 as well as chemically modified mRNA therapeutics. These new types of nucleic acid therapies are also a good fit with delivery by non-viral delivery approaches which has led to a renewed interest in lipid-based and other nanoformulations.
CITATION STYLE
Hart, S. L., & Harrison, P. T. (2017, June 1). Genetic therapies for cystic fibrosis lung disease. Current Opinion in Pharmacology. Elsevier Ltd. https://doi.org/10.1016/j.coph.2017.10.006
Mendeley helps you to discover research relevant for your work.